H2 Equity Partners has agreed to sell its minority stake in Optegra Eye Health Care to EssilorLuxottica, marking a significant alignment in the ophthalmology sector across Europe.

Target Information

H2 Equity Partners ("H2") has recently signed a definitive agreement to divest its minority stake in Optegra Eye Health Care, a rapidly growing and integrated ophthalmology platform operating in five prominent European markets: the United Kingdom, Czech Republic, Poland, Slovakia, and the Netherlands. Optegra has established itself as a leader in ophthalmic services, focusing on clinical excellence and a patient-centered approach, making it a notable player in the healthcare sector.

Since H2 acquired a majority stake in February 2021, it invested substantial capital and resources to drive Optegra's growth. Under H2's stewardship, Optegra expanded its operations, including the opening of new hospitals in the UK, executing strategic bolt-on acquisitions, and entering the Slovakian market, which significantly enhanced its revenue and profitability metrics, consolidating its position as a leading ophthalmology group across Europe.

Industry Overview

The ophthalmology sector in Europe is witnessing a transformative phase fueled by increasing demand for eye care services, driven by factors such as an aging population and rising incidence of eye disorders. The industry is p